|
1
|
Barrera J, Brake DA, Kamicker BJ, Purcell C, Kaptur R, Schieber T, Lechtenberg K, Miller TD, Ettyreddy D, Brough DE, Butman BT, Colby M, Neilan JG. Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle. Transbound Emerg Dis 2017; 65:447-455. [PMID: 29076657 DOI: 10.1111/tbed.12724] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Indexed: 11/27/2022]
Abstract
The safety of a replication-deficient, human adenovirus-vectored foot-and-mouth disease virus (FMDV) serotype A24 Cruzeiro capsid-based subunit vaccine (AdtA24) was evaluated in five independent safety studies. The target animal safety studies were designed in compliance with United States (U.S.) regulatory requirements (Title 9, U.S. Code of Federal Regulation [9CFR]) and international standard guidelines (VICH Topic GL-44) for veterinary live vaccines. The first three studies were conducted in a total of 22 vaccinees and demonstrated that the AdtA24 master seed virus (MSV) was safe, did not revert to virulence and was not shed or spread from vaccinees to susceptible cattle or pigs. The fourth safety study conducted in 10 lactating cows using an AdtA24 vaccine serial showed that the vaccine was completely absent from milk. The fifth safety study was conducted under typical U.S. production field conditions in 500 healthy beef and dairy cattle using two AdtA24 vaccine serials. These results demonstrated that the vaccine was safe when used per the product label recommendations. Additional data collected during these five studies confirmed that AdtA24 vaccinees developed FMDV A24 and the HAd5 vaccine vector serum neutralization antibodies that test negative in a FMDV non-structural protein antibody test, confirming AdtA24 vaccine's capability to differentiate infected from vaccinated animals (DIVA). In conclusion, results from this comprehensive set of cattle studies demonstrated the safety of the replication-deficient AdtA24 vaccine and fulfilled safety-related requirements for U.S. regulatory requirements.
Collapse
Affiliation(s)
- J Barrera
- The McConnell Group, Inc., Plum Island Animal Disease Center, Greenport, NY, USA
| | - D A Brake
- BioQuest Associates, LLC, Plum Island Animal Disease Center, Greenport, NY, USA
| | - B J Kamicker
- Leidos, Plum Island Animal Disease Center, Greenport, NY, USA
| | | | - R Kaptur
- Central States Research Centre, Oakland, NE, USA
| | - T Schieber
- Midwest Veterinary Service, Inc., Oakland, NE, USA
| | | | - T D Miller
- Benchmark Biolabs, Inc., Lincoln, NE, USA
| | | | | | | | - M Colby
- U.S. Department of Homeland Security Science and Technology Directorate, Washington, DC, USA
| | - J G Neilan
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, Greenport, NY, USA
| |
Collapse
|
|
2
|
Stokka GL, Lechtenberg K, Edwards T, MacGregor S, Voss K, Griffin D, Grotelueschen DM, Smith RA, Perino LJ. Lameness in feedlot cattle. Vet Clin North Am Food Anim Pract 2001; 17:189-207, viii. [PMID: 11320695 DOI: 10.1016/s0749-0720(15)30062-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
This article examines the various causes of lameness in feedlot cattle, with an emphasis on clinical signs, treatment, and prevention. Specific conditions are discussed, including interdigital necrobacillosis, laminitis, feedlot injuries, and feedlot lameness associated with Mycoplasma bovis. Immune management of the foot is also reviewed.
Collapse
Affiliation(s)
- G L Stokka
- Kansas State University, Manhattan, Kansas, USA
| | | | | | | | | | | | | | | | | |
Collapse
|